BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 36645283)

  • 21. [Epstein-Barr virus (Herpesviridae:
    Smirnova KV; Lubenskaya AK; Senyuta NB; Dushenkina TE; Gurtsevitch VE
    Vopr Virusol; 2023 Sep; 68(4):291-301. PubMed ID: 38156586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SPLUNC1 reduces the inflammatory response of nasopharyngeal carcinoma cells infected with the EB virus by inhibiting the TLR9/NF-κB pathway.
    Ou C; Sun Z; Zhang H; Xiong W; Ma J; Zhou M; Lu J; Zeng Z; Bo X; Chen P; Li G; Li X; Li X
    Oncol Rep; 2015 Jun; 33(6):2779-88. PubMed ID: 25891128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment of a nasopharyngeal carcinoma cell line capable of undergoing lytic Epstein-Barr virus reactivation.
    Yip YL; Lin W; Deng W; Jia L; Lo KW; Busson P; Vérillaud B; Liu X; Tsang CM; Lung ML; Tsao SW
    Lab Invest; 2018 Aug; 98(8):1093-1104. PubMed ID: 29769697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma.
    Paudel S; Warner BE; Wang R; Adams-Haduch J; Reznik AS; Dou J; Huang Y; Gao YT; Koh WP; Bäckerholm A; Yuan JM; Shair KHY
    Clin Cancer Res; 2022 Dec; 28(23):5221-5230. PubMed ID: 36165913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
    Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
    Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma Macrophage Inhibitory Cytokine-1 as a Complement of Epstein-Barr Virus Related Markers in Identifying Nasopharyngeal Carcinoma.
    Xing S; Li H; Pi Y; Zeng T; Huang Q; Ou G; Xue N
    Technol Cancer Res Treat; 2020; 19():1533033820956991. PubMed ID: 33025864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways.
    Lin C; Zong J; Lin W; Wang M; Xu Y; Zhou R; Lin S; Guo Q; Chen H; Ye Y; Zhang B; Pan J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):283. PubMed ID: 30477559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels.
    Guo X; Li T; Li F; Xu Y; Wang H; Cheng W; Tang J; Zhou G; Chen H; Ng M; Ji M; Ge S; Xia N
    Oral Oncol; 2019 Jun; 93():85-90. PubMed ID: 31109701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
    Xue N; Lin JH; Xing S; Liu D; Li SB; Lai YZ; Wang XP; Mao MJ; Zhong Q; Zeng MS; Liu WL
    Cancer Res Treat; 2019 Jan; 51(1):378-390. PubMed ID: 29807404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
    Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
    PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitation of DNA methylation in Epstein-Barr virus-associated nasopharyngeal carcinoma by bisulfite amplicon sequencing.
    Zhao W; Mo Y; Wang S; Midorikawa K; Ma N; Hiraku Y; Oikawa S; Huang G; Zhang Z; Murata M; Takeuchi K
    BMC Cancer; 2017 Jul; 17(1):489. PubMed ID: 28716111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EBV abortive lytic cycle promotes nasopharyngeal carcinoma progression through recruiting monocytes and regulating their directed differentiation.
    Xu X; Zhu N; Zheng J; Peng Y; Zeng MS; Deng K; Duan C; Yuan Y
    PLoS Pathog; 2024 Jan; 20(1):e1011934. PubMed ID: 38206974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
    Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
    Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
    Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
    mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus-coded miR-BART13 promotes nasopharyngeal carcinoma cell growth and metastasis via targeting of the NKIRAS2/NF-κB pathway.
    Xu YJ; Zhou R; Zong JF; Lin WS; Tong S; Guo QJ; Lin C; Lin SJ; Chen YX; Chen MR; Chen HL; Ye YB; Pan JJ
    Cancer Lett; 2019 Apr; 447():33-40. PubMed ID: 30684592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
    Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
    Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-Barr virus connection?
    Chen DY; Chen YM; Lan JL; Chen HH; Hsieh CW; Wey SJ; Lu JJ
    J Clin Virol; 2010 Dec; 49(4):290-5. PubMed ID: 20934910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma.
    Ka-Yue Chow L; Lai-Shun Chung D; Tao L; Chan KF; Tung SY; Cheong Ngan RK; Ng WT; Wing-Mui Lee A; Yau CC; Lai-Wan Kwong D; Ho-Fun Lee V; Lam KO; Liu J; Chen H; Dai W; Lung ML
    EBioMedicine; 2022 Dec; 86():104357. PubMed ID: 36371985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis.
    Shi F; He Y; Li J; Tang M; Li Y; Xie L; Zhao L; Hu J; Luo X; Zhou M; Liu N; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Jia W; Bode AM; Cao Y
    Mol Metab; 2020 Jun; 36():100966. PubMed ID: 32224436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.